Hans G. Cruz
Epalinges, VD, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Camidanlumab tesirine for relapsed or refractory classic Hodgkin lymphoma: a phase 2 study.
Journal: Blood advances
Published: December 10, 2024
Exposure-response analysis of Camidanlumab tesirine in patients with relapsed or refractory classical Hodgkin lymphoma and non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: June 14, 2022
Population pharmacokinetics analysis of camidanlumab tesirine in patients with relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma.
Journal: Cancer chemotherapy and pharmacology
Published: June 14, 2022
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study.
Journal: The Lancet. Haematology
Published: January 14, 2021
Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study.
Journal: Leukemia research
Published: March 20, 2020
Biomarker-guided clinical development of the first-in-class anti-inflammatory FPR2/ALX agonist ACT-389949.
Journal: British journal of clinical pharmacology
Published: July 13, 2016
Pharmacokinetics of the novel oral prostacyclin receptor agonist selexipag in subjects with hepatic or renal impairment.
Journal: British journal of clinical pharmacology
Published: July 20, 2015
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies.
Journal: Drug design, development and therapy
Published: May 09, 2014
Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.
Journal: CNS drugs
Published: March 15, 2014
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Journal: Journal of pharmaceutical sciences
Published: January 06, 2014
Pharmacokinetic and pharmacodynamic interactions between almorexant, a dual orexin receptor antagonist, and desipramine.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
Published: September 11, 2013
Showing 1-11 of 11
Last Updated: 09/26/2026